

## REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH BIPOLAR 1 DISORDER

1. **Practice guideline for the treatment of patients with bipolar disorder (revision).** *The American journal of psychiatry* 2002, **159**(4 Suppl):1-50.
2. AA Pharma Inc: **Lithmax (lithium Carbonate).** In: *CA Product Monograph.* Vaughan, ON; 2013.
3. AbbVie Inc: **Divalproex sodium.** In: *US Product Monograph.* 2017.
4. AbbVie Inc: **Depakene (valproic acid).** In: *US Product Monograph.* North Chicago, IL; 2017.
5. AbbVie Inc: **Depakote (divalproex).** In: *US Product Monograph.* North Chicago, IL; 2017.
6. Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindstrom L, Hammarlund-Udenaes M: **Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.** *J Psychiatr Res* 2008, **42**(11):884-893.
7. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M: **HLA-B locus in Caucasian patients with carbamazepine hypersensitivity.** *Pharmacogenomics* 2006, **7**(6):813-818.
8. Allergan USA Inc: **Vraylar (cariprazine)** In: *US Product Monograph.* Irvine, CA; 2016.
9. Allergan USA Inc: **Saphris (asenapine).** In: *US Product Monograph.* Irvine, CA; 2017.
10. Allergan USA Inc: **Vraylar (cariprazine).** In: *US Product Monograph.* Madison, NJ; 2018.
11. Amsterdam JD, Shults J: **Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study.** *The American journal of psychiatry* 2010, **167**(7):792-800.
12. Amsterdam JD, Lorenzo-Luaces L, Soeller I, Li SQ, Mao JJ, DeRubeis RJ: **Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective study.** *Journal of affective disorders* 2015, **185**:31-37.
13. Amstutz U, Ross CJ, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, Carleton BC: **HLA-A\*31:01 and HLA-B\*15:02 as genetic markers for carbamazepine hypersensitivity in children.** *Clinical pharmacology and therapeutics* 2013, **94**(1):142-149.
14. Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, Connolly MB, Ito S, Carleton BC: **Recommendations for HLA-B\*15:02 and HLA-A\*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.** *Epilepsia* 2014, **55**(4):496-506.
15. An DM, Wu XT, Hu FY, Yan B, Stefan H, Zhou D: **Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B\*1502 in a Han Chinese population.** *Epilepsy research* 2010, **92**(2-3):226-230.
16. ANI Pharmaceuticals Inc: **Lithobid (lithium).** In: *US Product Monograph.* Baudette, MN; 2018.
17. Apotex Inc: **Apo-Lithium Carbonate.** In: *CA Product Monograph.* Toronto, ON; 2013.

18. AstraZeneca Canada Inc: **Seroquel (quetiapine fumarate)**. In: *CA Product Monograph*. Mississauga, ON; 2015.
19. AstraZeneca Canada Inc: **Seroquel XR (quetiapine fumarate)**. In: *CA Product Monograph*. Mississauga, ON; 2015.
20. AstraZeneca Pharmaceuticals LP: **Seroquel (quetiapine)**. In: *US Product Monograph*. Wilmington, DE; 2017.
21. AstraZeneca Pharmaceuticals LP: **Seroquel XR (quetiapine fumarate)**. In: *US Product Monograph*. Wilmington, DE; 2018.
22. Azuma J, Hasunuma T, Kubo M, Miyatake M, Koue T, Higashi K, Fujiwara T, Kitahara S, Katano T, Hara S: **The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine**. *European journal of clinical pharmacology* 2012, **68**(1):29-37.
23. Bakker PR, van Harten PN, van Os J: **Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions**. *Molecular psychiatry* 2008, **13**(5):544-556.
24. Belgamwar RB, Ebrahim F, Campbell C: **Lithium in chronic renal failure: a case report**. *General hospital psychiatry* 2010, **32**(3):341 e343-345.
25. Berwaerts J, Lane R, Nuamah IF, Lim P, Remmerie B, Hough DW: **Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study**. *Journal of affective disorders* 2011, **129**(1-3):252-260.
26. Berwaerts J, Xu H, Nuamah I, Lim P, Hough D: **Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study**. *Journal of affective disorders* 2012, **136**(1-2):e51-60.
27. Berwaerts J, Melkote R, Nuamah I, Lim P: **A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode**. *Journal of affective disorders* 2012, **138**(3):247-258.
28. BGP Pharma ULC: **Depakene (valproic acid)**. In: *CA Product Monograph*. Etobicoke, ON; 2016.
29. BGP Pharma ULC: **Epival (divalproex)**. In: *CA Product Monograph*. Etobicoke, ON; 2016.
30. BGP Pharma ULC: **Epival (divalproex sodium)**. In: *CA Product Monograph*. Etobicoke, ON; 2017.
31. BGP Pharma ULC: **Depakene (valproic acid)**. In: *CA Product Monograph*. Etobicoke, ON; 2017.
32. Bork JA, Rogers T, Wedlund PJ, de Leon J: **A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A**. *The Journal of clinical psychiatry* 1999, **60**(7):469-476.
33. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG *et al*: **Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group**. *Jama* 1994, **271**(12):918-924.
34. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M: **Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial**. *The Journal of clinical psychiatry* 2010, **71**(2):130-137.

35. Bristol-Myers Squibb Canada: **Abilify (aripiprazole)**. In: *CA Product Monograph*. Montreal, QC; 2015.
36. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B, Roots I: **The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment**. *Clinical pharmacology and therapeutics* 2002, **72**(4):438-452.
37. Brown EB, McElroy SL, Keck PE, Jr., Deldar A, Adams DH, Tohen M, Williamson DJ: **A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression**. *The Journal of clinical psychiatry* 2006, **67**(7):1025-1033.
38. Brown R, Taylor MJ, Geddes J: **Aripiprazole alone or in combination for acute mania**. *The Cochrane database of systematic reviews* 2013(12):CD005000.
39. Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G: **Lithium for maintenance treatment of mood disorders**. *The Cochrane database of systematic reviews* 2001(3):CD003013.
40. Bushu Pharmaceutical Ltd: **Latuda (lurasidone)**. In: *US Product Monograph*. Marlborough, MA; 2010.
41. Cabaleiro T, Lopez-Rodriguez R, Ochoa D, Roman M, Novalbos J, Abad-Santos F: **Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects**. *Human psychopharmacology* 2013, **28**(3):205-214.
42. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD: **A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group**. *The Journal of clinical psychiatry* 1999, **60**(2):79-88.
43. Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte JA: **Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents**. *Pharmacogenetics and genomics* 2009, **19**(5):373-382.
44. Calver L, Drinkwater V, Gupta R, Page CB, Isbister GK: **Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomised controlled trial**. *The British journal of psychiatry : the journal of mental science* 2015, **206**(3):223-228.
45. Canadian Pharmacists Association: **Lithium [CPhA monograph]**. In: *RxTx*. Ottawa, ON; 2014.
46. Canadian Pharmacists Association: **Selective Serotonin Reuptake Inhibitors [CPhA monograph]**. In: *RxTx*. Ottawa, ON; 2014.
47. Canadian Pharmacists Association: **Haloperidol [CPhA monograph]**. In: *RxTx*. Ottawa, ON; 2016.
48. Ceron-Litvoc D, Soares BG, Geddes J, Litvoc J, de Lima MS: **Comparison of carbamazepine and lithium in treatment of bipolar disorder: a systematic review of randomized controlled trials**. *Human psychopharmacology* 2009, **24**(1):19-28.
49. Chang CC, Too CL, Murad S, Hussein SH: **Association of HLA-B\*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population**. *International journal of dermatology* 2011, **50**(2):221-224.
50. Cheung YK, Cheng SH, Chan EJ, Lo SV, Ng MH, Kwan P: **HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese**. *Epilepsia* 2013, **54**(7):1307-1314.

51. Chiesa A, Chierzi F, De Ronchi D, Serretti A: **Quetiapine for bipolar depression: a systematic review and meta-analysis.** *International clinical psychopharmacology* 2012, **27**(2):76-90.
52. Cho HY, Lee YB: **Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes.** *Archives of pharmacal research* 2006, **29**(6):525-533.
53. Chong KW, Chan DW, Cheung YB, Ching LK, Hie SL, Thomas T, Ling S, Tan EC: **Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B\*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore.** *Archives of disease in childhood* 2014, **99**(6):581-584.
54. Chung WH, Hung SI, Hong HS, Hsieh MS, Yang LC, Ho HC, Wu JY, Chen YT: **Medical genetics: a marker for Stevens-Johnson syndrome.** *Nature* 2004, **428**(6982):486.
55. Cipriani A, Rendell JM, Geddes JR: **Haloperidol alone or in combination for acute mania.** *The Cochrane database of systematic reviews* 2006(3):CD004362.
56. Cipriani A, Rendell JM, Geddes J: **Olanzapine in long-term treatment for bipolar disorder.** *The Cochrane database of systematic reviews* 2009(1):CD004367.
57. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spinelli LM, Goodwin GM, Geddes JR: **Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis.** *Lancet (London, England)* 2011, **378**(9799):1306-1315.
58. Cipriani A, Reid K, Young AH, Macritchie K, Geddes J: **Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.** *The Cochrane database of systematic reviews* 2013(10):CD003196.
59. Citrome L: **Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.** *The Journal of clinical psychiatry* 2007, **68**(12):1876-1885.
60. Connolly KR, Thase ME: **The clinical management of bipolar disorder: a review of evidence-based guidelines.** *The primary care companion for CNS disorders* 2011, **13**(4).
61. Correia CT, Almeida JP, Santos PE, Sequeira AF, Marques CE, Miguel TS, Abreu RL, Oliveira GG, Vicente AM: **Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions.** *The pharmacogenomics journal* 2010, **10**(5):418-430.
62. Cupp M: **Comparison of atypical antipsychotics.** In: *Pharmacist's Letter/Prescriber's Letter.* Stockton, CA; 2016.
63. Cutler AJ, Datto C, Nordenhem A, Minkwitz M, Acevedo L, Darko D: **Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.** *Clinical therapeutics* 2011, **33**(11):1643-1658.
64. Czerwensky F, Leucht S, Steimer W: **MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?** *The international journal of neuropsychopharmacology* 2013, **16**(9):2103-2109.
65. Dardennes R, Even C, Bange F, Heim A: **Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders. A meta-analysis.** *The British journal of psychiatry: the journal of mental science* 1995, **166**(3):378-381.

66. de Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ: **Polymorphic variations in GSTM1, GSTT1, Pgp, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.** *Journal of clinical psychopharmacology* 2005, **25**(5):448-456.
67. de Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ: **A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.** *Pharmacopsychiatry* 2007, **40**(3):93-102.
68. Desai M, Tanus-Santos JE, Li L, Gorski JC, Arefayene M, Liu Y, Desta Z, Flockhart DA: **Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6.** *The pharmacogenomics journal* 2003, **3**(2):105-113.
69. Dos Santos-Junior A, Henriques TB, de Mello MP, Della Torre OH, Paes LA, Ferreira-Neto AP, Sewaybricker LE, Fontana TS, Celeri EH, Guerra-Junior G *et al*: **Pharmacogenetics of risperidone and cardiovascular risk in children and adolescents.** *Int J Endocrinol* 2016, **2016**:5872423.
70. Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Nemeth G, Vieta E, Calabrese JR, Yatham LN: **An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression.** *The American journal of psychiatry* 2016, **173**(3):271-281.
71. **Pharmacogenomics guidelines** [<https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf>]
72. Education Medicaid Integrity Contractor for the CMS Medicaid Integrity Program: **Atypical antipsychotics: US Food and Drug Administration-approved indications and dosages for use in adults.** In.: Department of Health and Human Services, USA; 2013.
73. Eli Lilly and Company: **Zyprexa (olanzapine).** In: *US Product Monograph.* Indianapolis , IN; 2018.
74. Eli Lilly Canada Inc: **Prozac (fluoxetine).** In: *CA Product Monograph.* Toronto, Ontario: Eli Lilly Canada Inc.; 2016.
75. Eli Lilly Canada Inc: **Zyprexa (olanzapine).** In: *CA Product Monograph.* Toronto, Ontario; 2016.
76. Ellingrod VL, Miller D, Schultz SK, Wehring H, Arndt S: **CYP2D6 polymorphisms and atypical antipsychotic weight gain.** *Psychiatric genetics* 2002, **12**(1):55-58.
77. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F, Holman TL, Miller D: **Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine.** *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 2005, **134B**(1):76-78.
78. Espadaler J, Tuson M, Lopez-Ibor JM, Lopez-Ibor F, Lopez-Ibor MI: **Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis.** *CNS Spectr* 2017, **22**(4):315-324.
79. Fountoulakis KN, Vieta E: **Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review.** *Annals of general psychiatry* 2009, **8**:16.
80. Fountoulakis KN, Vieta E, Schmidt F: **Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis.** *Journal of affective disorders* 2011, **133**(3):361-370.

81. Fricke-Galindo I, Martinez-Juarez IE, Monroy-Jaramillo N, Jung-Cook H, Falfan-Valencia R, Ortega-Vazquez A, Alonso-Vilatela ME, Lopez-Lopez M: **HLA-A\*02:01:01/-B\*35:01:01/-C\*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients.** *Pharmacogenomics* 2014, **15**(15):1881-1891.
82. Gardner DM, Baldessarini RJ, Waraich P: **Modern antipsychotic drugs: a critical overview.** *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne* 2005, **172**(13):1703-1711.
83. Gash AJ, Chhabra S, Eccleston D: **Lithium augmentation in a case of renal impairment: risk vs. benefit.** *Journal of affective disorders* 1995, **34**(1):51-53.
84. Geddes JR, Calabrese JR, Goodwin GM: **Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials.** *The British journal of psychiatry : the journal of mental science* 2009, **194**(1):4-9.
85. Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, Morriss R, Alder N, Juszczak E: **Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial.** *Lancet (London, England)* 2010, **375**(9712):385-395.
86. Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, Tsai SH, Wu TL, Bellon T, Tamouza R *et al*: **HLA-A\*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis.** *The pharmacogenomics journal* 2014, **14**(3):281-288.
87. Gibbons RD, Hur K, Brown CH, Mann JJ: **Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder.** *Archives of general psychiatry* 2009, **66**(12):1354-1360.
88. GlaxoSmithKline Inc.: **Lamictal (lamotrigine).** In: *CA Product Monograph.* Mississauga, ON; 2016.
89. GlaxoSmithKline LLC: **Lamictal (lamotrigine).** In: *US Product Monograph.* Research Triangle Park, NC; 2017.
90. Godlewska BR, Olajosy-Hilkesberger L, Ciwoniuk M, Olajosy M, Marmurowska-Michalowska H, Limon J, Landowski J: **Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene.** *The pharmacogenomics journal* 2009, **9**(4):234-241.
91. Goikolea JM, Colom F, Capapey J, Torres I, Valenti M, Grande I, Undurraga J, Vieta E: **Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania.** *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 2013, **23**(4):305-316.
92. Goikolea JM, Colom F, Torres I, Capapey J, Valenti M, Undurraga J, Grande I, Sanchez-Moreno J, Vieta E: **Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.** *Journal of affective disorders* 2013, **144**(3):191-198.
93. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D: **Suicide risk in bipolar disorder during treatment with lithium and divalproex.** *Jama* 2003, **290**(11):1467-1473.

94. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, Coghill DR, Fazel S, Geddes JR, Grunze H *et al*: **Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.** *Journal of psychopharmacology (Oxford, England)* 2016, **30**(6):495-553.
95. Grande I, Berk M, Birmaher B, Vieta E: **Bipolar disorder.** *Lancet (London, England)* 2016, **387**(10027):1561-1572.
96. Grossman F, Potter WZ, Brown EA, Maislin G: **A double-blind study comparing idazoxan and bupropion in bipolar depressed patients.** *Journal of affective disorders* 1999, **56**(2-3):237-243.
97. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, Kasper S: **The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder.** *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry* 2013, **14**(3):154-219.
98. Haddad PM, Sharma SG: **Adverse effects of atypical antipsychotics : differential risk and clinical implications.** *CNS Drugs* 2007, **21**(11):911-936.
99. Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DP: **Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records.** *World psychiatry : official journal of the World Psychiatric Association (WPA)* 2016, **15**(1):53-58.
100. Hayes JF, Pitman A, Marston L, Walters K, Geddes JR, King M, Osborn DP: **Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A UK Population-Based Electronic Health Records Study.** *JAMA psychiatry* 2016, **73**(6):630-637.
101. He XJ, Jian LY, He XL, Wu Y, Xu YY, Sun XJ, Miao LY, Zhao LM: **Association between the HLA-B\*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China.** *Pharmacological reports : PR* 2013, **65**(5):1256-1262.
102. Hendset M, Hermann M, Lunde H, Refsum H, Molden E: **Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.** *European journal of clinical pharmacology* 2007, **63**(12):1147-1151.
103. Hendset M, Molden E, Knape M, Hermann M: **Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.** *Therapeutic drug monitoring* 2014, **36**(1):80-85.
104. HLS Therapeutics Inc: **Clozaril (clozapine).** In: *CA Product Monograph.* Etobicoke, ON; 2016.
105. HLS Therapeutics Inc: **Clozaril (clozapine).** In: *US Product Monograph.* Rosemont, PA; 2018.
106. Houston JP, Kohler J, Bishop JR, Ellingrod VL, Ostbye KM, Zhao F, Conley RR, Poole Hoffmann V, Fijal BA: **Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.** *The Journal of clinical psychiatry* 2012, **73**(8):1077-1086.
107. Hsiao YH, Hui RC, Wu T, Chang WC, Hsieh MS, Yang CH, Ho HC, Chang YG, Chen MJ, Lin JY *et al*: **Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations.** *Journal of dermatological science* 2014, **73**(2):101-109.

108. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW *et al*: **Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.** *Pharmacogenetics and genomics* 2006, **16**(4):297-306.
109. Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC, Chu CY, Chen YT: **Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.** *Pharmacogenomics* 2010, **11**(3):349-356.
110. Ikeda M, Yamanouchi Y, Kinoshita Y, Kitajima T, Yoshimura R, Hashimoto S, O'Donovan MC, Nakamura J, Ozaki N, Iwata N: **Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.** *Pharmacogenomics* 2008, **9**(10):1437-1443.
111. Inada T, Senoo H, Iijima Y, Yamauchi T, Yagi G: **Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.** *Psychiatric genetics* 2003, **13**(3):163-168.
112. Ito A, Shimada H, Ishikawa K, Takeo N, Hatano Y, Katagiri K, Kohno K, Araki Y, Terao T, Kojima H *et al*: **Association between HLA-DRB1\*0405, -DQB1\*0401 and -DQA1\*0303 alleles and lamotrigine-induced cutaneous adverse drug reactions. A pilot case-control study from Japan.** *Journal of affective disorders* 2015, **179**:47-50.
113. Janssen Inc: **Risperdal (risperidone oral).** In: *CA Product Monograph.* Toronto, ON; 2014.
114. Janssen Inc: **Invega Sustenna (paliperidone palmitate injectable).** In: *CA Product Monograph.* Toronto, ON; 2015.
115. Janssen Inc: **Risperdal Consta (risperidone IM injection).** In: *CA Product Monograph.* Toronto, ON; 2015.
116. Janssen Inc: **Invega (paliperidone extended release).** In: *CA Product Monograph.* Toronto, ON; 2016.
117. Janssen Pharmaceuticals Inc: **Haldol Deconoate (haloperidol).** In: *US Product Monograph.* Titusville, NJ; 2017.
118. Janssen Pharmaceuticals Inc: **Risperdal Consta (risperidone IM injection).** In: *US Product Monograph.* Titusville, NJ; 2018.
119. Janssen Pharmaceuticals Inc: **Risperdal (risperidone oral).** In: *US Product Monograph.* Titusville, NJ; 2018.
120. Janssen Pharmaceuticals Inc: **Invega (paliperidone extended release).** In: *US Product Monograph.* Titusville, NJ; 2018.
121. Janssen Pharmaceuticals Inc: **Invega Trinza (paliperidone injectable).** In: *US Product Monograph.* Titusville, NJ; 2019.
122. Kakihara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K, Yamada Y, Ueda N, Ohmori O, Nakamura J: **Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.** *International clinical psychopharmacology* 2005, **20**(2):71-78.
123. Kanba S, Kawasaki H, Ishigooka J, Sakamoto K, Kinoshita T, Kuroki T: **A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study).** *The*



124. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S *et al*: **HLA-B\*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.** *Epilepsia* 2010, **51**(12):2461-2465.
125. Kashiwagi M, Aihara M, Takahashi Y, Yamazaki E, Yamane Y, Song Y, Muramatsu M, Ikezawa Z: **Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients.** *The Journal of dermatology* 2008, **35**(10):683-685.
126. Kato D, Kawanishi C, Kishida I, Furuno T, Matsumura T, Hasegawa H, Hirayasu Y: **Delirium resolving upon switching from risperidone to quetiapine: implication of CYP2D6 genotype.** *Psychosomatics* 2005, **46**(4):374-375.
127. Kazeem GR, Cox C, Aponte J, Messenheimer J, Brazell C, Nelsen AC, Nelson MR, Foot E: **High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients.** *Pharmacogenetics and genomics* 2009, **19**(9):661-665.
128. Keck PE, Jr., Versiani M, Potkin S, West SA, Giller E, Ice K: **Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.** *The American journal of psychiatry* 2003, **160**(4):741-748.
129. Kemp DE, Johnson E, Wang WV, Tohen M, Calabrese JR: **Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone.** *The Journal of clinical psychiatry* 2011, **72**(9):1236-1241.
130. Kennedy SH, Parikh S, Grigoriadis S: **Depression.** In: *Therapeutics [Internet]*. Edited by Jovaisas B. Ottawa (ON): Canadian Pharmacists Association; 2016.
131. Khor AH, Lim KS, Tan CT, Wong SM, Ng CC: **HLA-B\*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis.** *Epilepsia* 2014, **55**(11):e120-124.
132. Kim SH, Lee KW, Song WJ, Kim SH, Jee YK, Lee SM, Kang HR, Park HW, Cho SH, Park SH *et al*: **Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans.** *Epilepsy research* 2011, **97**(1-2):190-197.
133. Kim BK, Jung JW, Kim TB, Chang YS, Park HS, Moon J, Lee ST, Jung KH, Jung KY, Chu K *et al*: **HLA-A\*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population.** *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology* 2017, **118**(5):629-630.
134. Kohnke MD, Griese EU, Stosser D, Gaertner I, Barth G: **Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone.** *Pharmacopsychiatry* 2002, **35**(3):116-118.
135. Kubo M, Koue T, Maune H, Fukuda T, Azuma J: **Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.** *Drug metabolism and pharmacokinetics* 2007, **22**(5):358-366.
136. Kulkantrakorn K, Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Prabmechai N, Vannaprasaht S, Chumworathayi P, Chen P, Sritipsukho P: **HLA-B\*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai**

- patients with neuropathic pain.** *Pain practice : the official journal of World Institute of Pain* 2012, **12**(3):202-208.
137. Laika B, Leucht S, Heres S, Schneider H, Steimer W: **Pharmacogenetics and olanzapine treatment: CYP1A2\*1F and serotonergic polymorphisms influence therapeutic outcome.** *The pharmacogenomics journal* 2010, **10**(1):20-29.
  138. Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT, Chang WH: **Risperidone-related weight gain: genetic and nongenetic predictors.** *Journal of clinical psychopharmacology* 2006, **26**(2):128-134.
  139. Leckband SG, Kelsoe JR, Dunnenberger HM, George AL, Jr., Tran E, Berger R, Muller DJ, Whirl-Carrillo M, Caudle KE, Pirmohamed M *et al*: **Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.** *Clinical pharmacology and therapeutics* 2013, **94**(3):324-328.
  140. Lee M, Jensen B, Regier L: **Bipolar Disorder treatment chart.** In: *RxFiles*. Saskatoon, SK: Saskatoon Health Region; 2016.
  141. Lee M, Jensen B, Regier L: **Antipsychotics comparison chart.** In: *RxFiles* Saskatoon, SK: Saskatoon Health Region; 2016.
  142. Lee M, Jensen B, Regier L: **Antidepressants comparison chart.** In: *RxFiles*. Saskatoon, SK: Saskatoon Health Region; 2016.
  143. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J: **Practice guideline for the treatment of patients with schizophrenia, second edition.** *The American journal of psychiatry* 2004, **161**(2 Suppl):1-56.
  144. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, Woerner MG, Kane JM, Goldman D, Malhotra AK: **DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.** *The American journal of psychiatry* 2006, **163**(3):529-531.
  145. Li LJ, Hu FY, Wu XT, An DM, Yan B, Zhou D: **Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese.** *Epilepsy research* 2013, **106**(1-2):296-300.
  146. Li XB, Tang YL, Wang CY, de Leon J: **Clozapine for treatment-resistant bipolar disorder: a systematic review.** *Bipolar disorders* 2015, **17**(3):235-247.
  147. Lilly USA LLC: **Prozac (fluoxetine).** In: *US Product Monograph*. Indianapolis, IN; 2017.
  148. Lisbeth P, Vincent H, Kristof M, Bernard S, Manuel M, Hugo N: **Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.** *European journal of clinical pharmacology* 2016, **72**(2):175-184.
  149. Llerena A, Berecz R, Dorado P, de la Rubia A: **QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.** *Journal of psychopharmacology (Oxford, England)* 2004, **18**(2):189-193.
  150. Llerena A, de la Rubia A, Berecz R, Dorado P: **Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.** *Pharmacopsychiatry* 2004, **37**(2):69-73.

151. Lochareernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, Kangwanshiratada O, Hirankarn N, Suphapeetiporn K, Shotelersuk V: **Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B\*1502 allele in Thai population.** *Epilepsia* 2008, **49**(12):2087-2091.
152. Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, Calabrese JR: **Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.** *The American journal of psychiatry* 2014, **171**(2):169-177.
153. Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, Sachs G: **Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.** *The American journal of psychiatry* 2014, **171**(2):160-168.
154. Lopez-Rodriguez R, Cabaleiro T, Ochoa D, Roman M, Borobia AM, Carcas AJ, Ayuso C, Novalbos J, Abad-Santos F: **Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers.** *Pharmacogenomics* 2013, **14**(10):1203-1214.
155. Ma X, Maimaitirexiati T, Zhang R, Gui X, Zhang W, Xu G, Hu G: **HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.** *International journal of psychiatry in clinical practice* 2014, **18**(4):229-242.
156. Macritchie K, Geddes JR, Scott J, Haslam D, de Lima M, Goodwin G: **Valproate for acute mood episodes in bipolar disorder.** *The Cochrane database of systematic reviews* 2003(1):CD004052.
157. Malhi GS: **Have the CANMAT bipolar guidelines transmogrified from do matter to can matter?** *Bipolar disorders* 2013, **15**(1):54-57.
158. Malhotra AK, Correll CU, Chowdhury NI, Muller DJ, Gregersen PK, Lee AT, Tiwari AK, Kane JM, Fleischhacker WW, Kahn RS *et al*: **Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.** *Archives of general psychiatry* 2012, **69**(9):904-912.
159. Marcus R, Khan A, Rollin L, Morris B, Timko K, Carson W, Sanchez R: **Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study.** *Bipolar disorders* 2011, **13**(2):133-144.
160. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PI *et al*: **HLA-A\*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.** *The New England journal of medicine* 2011, **364**(12):1134-1143.
161. McElroy SL, Martens BE, Creech RS, Welge JA, Jefferson L, Guerdjikova AI, Keck PE, Jr.: **Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania.** *The Journal of clinical psychiatry* 2010, **71**(5):557-565.
162. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH: **A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).** *The Journal of clinical psychiatry* 2010, **71**(2):163-174.

163. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J: **A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.** *Bipolar disorders* 2009, **11**(7):673-686.
164. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J: **Asenapine versus olanzapine in acute mania: a double-blind extension study.** *Bipolar disorders* 2009, **11**(8):815-826.
165. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J: **Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.** *Journal of affective disorders* 2010, **122**(1-2):27-38.
166. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J: **Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.** *Journal of affective disorders* 2010, **126**(3):358-365.
167. Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB, Dave DM, Goyal RK: **Association of HLA-B\*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians.** *Indian journal of dermatology, venereology and leprology* 2009, **75**(6):579-582.
168. Merck Canada Inc.: **Saphris (asenapine).** In: *CA Product Monograph*. Saint-Laurent, QC; 2016.
169. Mihara K, Suzuki A, Kondo T, Yasui N, Furukori H, Nagashima U, Otani K, Kaneko S, Inoue Y: **Effects of the CYP2D6\*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.** *Clinical pharmacology and therapeutics* 1999, **65**(3):291-294.
170. Moon J, Park HK, Chu K, Sunwoo JS, Byun JI, Lim JA, Kim TJ, Shin JW, Lee ST, Jung KH *et al*: **The HLA-A\*2402/Cw\*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population.** *Epilepsia* 2015, **56**(10):e161-167.
171. Muench J, Hamer AM: **Adverse effects of antipsychotic medications.** *American family physician* 2010, **81**(5):617-622.
172. Mulder H, Franke B, van der-Beek van der AA, Arends J, Wilmink FW, Scheffer H, Egberts AC: **The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia.** *Journal of clinical psychopharmacology* 2007, **27**(4):338-343.
173. Mulder H, Cohen D, Scheffer H, Gispens-de Wied C, Arends J, Wilmink FW, Franke B, Egberts AC: **HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study.** *Journal of clinical psychopharmacology* 2009, **29**(1):16-20.
174. Muller DJ, Zai CC, Sicard M, Remington E, Souza RP, Tiwari AK, Hwang R, Likhodi O, Shaikh S, Freeman N *et al*: **Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain.** *The pharmacogenomics journal* 2012, **12**(2):156-164.
175. National Institute for Health and Care Excellence: **Bipolar disorder: assessment and management. [NICE Guideline CG185].** In.; 2014.
176. Nguyen DV, Chu HC, Nguyen DV, Phan MH, Craig T, Baumgart K, van Nunen S: **HLA-B\*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese.** *Asia Pacific allergy* 2015, **5**(2):68-77.
177. Nielsen J, Kane JM, Correll CU: **Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study.** *Bipolar disorders* 2012, **14**(8):863-869.

178. Nierenberg AA, Friedman ES, Bowden CL, Sylvia LG, Thase ME, Ketter T, Ostacher MJ, Leon AC, Reilly-Harrington N, Iosifescu DV *et al*: **Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium.** *The American journal of psychiatry* 2013, **170**(1):102-110.
179. Nierenberg AA, McElroy SL, Friedman ES, Ketter TA, Shelton RC, Deckersbach T, McInnis MG, Bowden CL, Tohen M, Kocsis JH *et al*: **Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder.** *The Journal of clinical psychiatry* 2016, **77**(1):90-99.
180. Niihara H, Kakamu T, Fujita Y, Kaneko S, Morita E: **HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population.** *The Journal of dermatology* 2012, **39**(7):594-601.
181. Nivoli AM, Colom F, Murru A, Pacchiarotti I, Castro-Loli P, Gonzalez-Pinto A, Fountoulakis KN, Vieta E: **New treatment guidelines for acute bipolar depression: a systematic review.** *Journal of affective disorders* 2011, **129**(1-3):14-26.
182. Nolen WA, Weisler RH: **The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144).** *Bipolar disorders* 2013, **15**(1):100-109.
183. Novartis Pharmaceuticals Canada Inc: **Tegretol (carbamazepine).** In: *CA Product Monograph.* Dorval, QC; 2014.
184. Novartis Pharmaceuticals Corporation: **Tegretol (carbamazepine).** In: *US Product Monograph.* East Hanover, NJ; 2015.
185. Nozawa M, Ohnuma T, Matsubara Y, Sakai Y, Hatano T, Hanzawa R, Shibata N, Arai H: **The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).** *Therapeutic drug monitoring* 2008, **30**(1):35-40.
186. Nurmi EL, Spilman SL, Whelan F, Scahill LL, Aman MG, McDougale CJ, Arnold LE, Handen B, Johnson C, Sukhodolsky DG *et al*: **Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies.** *Translational psychiatry* 2013, **3**:e274.
187. Ohara K, Nagai M, Tani K, Nakamura Y, Ino A, Ohara K: **Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia.** *Psychiatry research* 1998, **81**(2):117-123.
188. Ohara K, Tanabu S, Yoshida K, Ishibashi K, Ikemoto K, Shibuya H: **Effects of smoking and cytochrome P450 2D6\*10 allele on the plasma haloperidol concentration/dose ratio.** *Progress in neuro-psychopharmacology & biological psychiatry* 2003, **27**(6):945-949.
189. Ohnuma T, Shibata N, Matsubara Y, Arai H: **Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6.** *British journal of clinical pharmacology* 2003, **56**(3):315-320.

190. Ostacher MJ, Suppes T, Swann AC, Eudicone JM, Landsberg W, Baker RA, Carlson BX: **Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania.** *International journal of bipolar disorders* 2015, **3**:11.
191. Otsuka America Pharmaceutical Inc: **Abilify Maintena (aripiprazole depot).** In: *US Product Monograph.* Rockville, MD; 2013.
192. Otsuka America Pharmaceutical Inc: **Abilify (aripiprazole).** In: *US Product Monograph.* Rockville, MD; 2017.
193. Otsuka Canada Pharmaceutical Inc: **Abilify Maintena (aripiprazole depot).** In: *CA Product Monograph.* Saint-Laurent, QC; 2016.
194. Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y, Ikezawa Z, Iijima M, Shiohara T, Hashimoto K *et al*: **Genome-wide association study identifies HLA-A\*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population.** *Human molecular genetics* 2011, **20**(5):1034-1041.
195. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Post RM, Berk M, Goodwin GM, Sachs GS *et al*: **The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.** *The American journal of psychiatry* 2013, **170**(11):1249-1262.
196. Pan L, Vander Stichele R, Rosseel MT, Berlo JA, De Schepper N, Belpaire FM: **Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients.** *Therapeutic drug monitoring* 1999, **21**(5):489-497.
197. Panagiotidis G, Arthur HW, Lindh JD, Dahl ML, Sjoqvist F: **Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.** *Therapeutic drug monitoring* 2007, **29**(4):417-422.
198. Parikh SV: **Bipolar Disorder.** In: *RxTx.* Edited by Jovaisas B. Ottawa, ON: Canadian Pharmacists Association; 2016.
199. Parikh SV: **Bipolar Disorder.** In: *RxTx.* Ottawa, ON: Canadian Pharmacists Association; 2018.
200. Park JY, Shon JH, Kim KA, Jung HJ, Shim JC, Yoon YR, Cha IJ, Shin JG: **Combined effects of itraconazole and CYP2D6\*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.** *Journal of clinical psychopharmacology* 2006, **26**(2):135-142.
201. Park HJ, Kim YJ, Kim DH, Kim J, Park KH, Park JW, Lee JH: **HLA allele frequencies in 5802 Koreans: Varied allele types associated with SJS/TEN according to culprit drugs.** *Yonsei medical journal* 2016, **57**(1):118-126.
202. Patkar AA, Pae CU, Vohringer PA, Mauer S, Narasimhan M, Dalley S, Loebel A, Masand PS, Ghaemi SN: **A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder.** *Journal of clinical psychopharmacology* 2015, **35**(3):319-323.
203. Pfizer Canada Inc: **Zeldox (ziprasidone).** In: *CA Product Monograph.* Kirkland, QC; 2016.
204. Phillips EJ, Sukasem C, Whirl-Carrillo M, Muller DJ, Dunnenberger HM, Chantratita W, Goldspiel B, Chen YT, Carleton BC, George AL, Jr. *et al*: **Clinical Pharmacogenetics Implementation**

**Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update.** *Clinical pharmacology and therapeutics* 2018, **103**(4):574-581.

205. Poolsup N, Li Wan Po A, de Oliveira IR: **Systematic overview of lithium treatment in acute mania.** *Journal of clinical pharmacy and therapeutics* 2000, **25**(2):139-156.
206. Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, Kupka RW, Suppes T, McElroy S, Keck PE, Denicoff KD *et al*: **Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline.** *The British journal of psychiatry : the journal of mental science* 2006, **189**:124-131.
207. Price AL, Marzani-Nissen GR: **Bipolar disorders: a review.** *American family physician* 2012, **85**(5):483-493.
208. Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V: **Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder.** *Biological psychiatry* 2010, **68**(2):156-162.
209. Ramirez E, Bellon T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, Moreno Hidalgo MA, Castaner JL, Cabanas R, Fiandor A *et al*: **Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population.** *Pharmacological research* 2017, **115**:168-178.
210. Rendell JM, Gijnsman HJ, Keck P, Goodwin GM, Geddes JR: **Olanzapine alone or in combination for acute mania.** *The Cochrane database of systematic reviews* 2003(3):CD004040.
211. Rendell JM, Gijnsman HJ, Bauer MS, Goodwin GM, Geddes GR: **Risperidone alone or in combination for acute mania.** *The Cochrane database of systematic reviews* 2006(1):CD004043.
212. Rendell JM, Geddes JR: **Risperidone in long-term treatment for bipolar disorder.** *The Cochrane database of systematic reviews* 2006(4):CD004999.
213. Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Muller-Arends A, Weber K, Zach J, Muller N, Moller HJ: **Risperidone plasma levels, clinical response and side-effects.** *European archives of psychiatry and clinical neuroscience* 2005, **255**(4):261-268.
214. Risselada AJ, Mulder H, Heerdink ER, Gonera RK, Egberts TCG: **Association between the HTR2C rs1414334 and ADRA2A 1291 C/G polymorphisms and lipid levels in obese patients.** In: *Genetic determinants for metabolic abnormalities.* edn.; 2012: 107.
215. Roerig Div of Pfizer Inc: **Geodon (ziprasidone).** In: *US Product Monograph.* New York, NY; 2018.
216. Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L: **Risperidone metabolism in relation to CYP2D6\*10 allele in Korean schizophrenic patients.** *European journal of clinical pharmacology* 2001, **57**(9):671-675.
217. Roh HK, Chung JY, Oh DY, Park CS, Svensson JO, Dahl ML, Bertilsson L: **Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.** *British journal of clinical pharmacology* 2001, **52**(3):265-271.
218. Roke Y, van Harten PN, Franke B, Galesloot TE, Boot AM, Buitelaar JK: **The effect of the Taq1A variant in the dopamine D(2) receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.** *Pharmacogenetics and genomics* 2013, **23**(9):487-493.

219. Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF: **A double-blind trial of bupropion versus desipramine for bipolar depression.** *The Journal of clinical psychiatry* 1994, **55**(9):391-393.
220. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL: **Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.** *The American journal of psychiatry* 2002, **159**(7):1146-1154.
221. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ *et al*: **Effectiveness of adjunctive antidepressant treatment for bipolar depression.** *The New England journal of medicine* 2007, **356**(17):1711-1722.
222. Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, Kasuba B: **Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.** *The Journal of clinical psychiatry* 2011, **72**(10):1413-1422.
223. Sachs GS, Vanderburg DG, Karayal ON, Kolluri S, Bachinsky M, Cavus I: **Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.** *The Journal of clinical psychiatry* 2012, **73**(11):1412-1419.
224. Sajatovic M, Coconcea N, Ignacio RV, Blow FC, Hays RW, Cassidy KA, Meyer WJ: **Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial.** *The Journal of clinical psychiatry* 2008, **69**(1):41-46.
225. Sajatovic M, Dines P, Fuentes-Casiano E, Athey M, Cassidy KA, Sams J, Clegg K, Locala J, Stagno S, Tatsuoka C: **Asenapine in the treatment of older adults with bipolar disorder.** *International journal of geriatric psychiatry* 2015, **30**(7):710-719.
226. Sandoz Canada Inc: **Haloperidol LA.** In: *CA Product Monograph.* Boucherville, QC; 2013.
227. Scherk H, Pajonk FG, Leucht S: **Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.** *Archives of general psychiatry* 2007, **64**(4):442-455.
228. Scordo MG, Spina E, Facciola G, Avenoso A, Johansson I, Dahl ML: **Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.** *Psychopharmacology* 1999, **147**(3):300-305.
229. Shafti SS: **Olanzapine vs. lithium in management of acute mania.** *Journal of affective disorders* 2010, **122**(3):273-276.
230. Shen YC, Chen SF, Chen CH, Lin CC, Chen SJ, Chen YJ, Luu SU: **Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.** *J Psychiatr Res* 2009, **43**(6):600-606.
231. Shi YW, Min FL, Liu XR, Zan LX, Gao MM, Yu MJ, Liao WP: **Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population.** *Basic & clinical pharmacology & toxicology* 2011, **109**(1):42-46.
232. Shi YW, Min FL, Qin B, Zou X, Liu XR, Gao MM, Wang Q, Zhou JQ, Liao WP: **Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese:**



- genetic markers besides B\*1502?** *Basic & clinical pharmacology & toxicology* 2012, **111**(1):58-64.
233. Shi YW, Min FL, Zhou D, Qin B, Wang J, Hu FY, Cheung YK, Zhou JH, Hu XS, Zhou JQ *et al*: **HLA-A\*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions.** *Neurology* 2017, **88**(23):2183-2191.
234. Shimoda K, Morita S, Yokono A, Someya T, Hirokane G, Sunahara N, Takahashi S: **CYP2D6\*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients.** *Therapeutic drug monitoring* 2000, **22**(4):392-396.
235. Sidor MM, Macqueen GM: **Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis.** *The Journal of clinical psychiatry* 2011, **72**(2):156-167.
236. Silva MT, Zimmermann IR, Galvao TF, Pereira MG: **Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis.** *Journal of affective disorders* 2013, **146**(3):310-318.
237. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D: **Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy.** *Acta psychiatrica Scandinavica* 2007, **115**(1):12-20.
238. Someya T, Suzuki Y, Shimoda K, Hirokane G, Morita S, Yokono A, Inoue Y, Takahashi S: **The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.** *Psychiatry and clinical neurosciences* 1999, **53**(5):593-597.
239. Someya T, Shimoda K, Suzuki Y, Sato S, Kawashima Y, Hirokane G, Morita S, Yokono A, Takahashi S: **Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population.** *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology* 2003, **28**(8):1501-1505.
240. Srivastava S, Wang PW, Hill SJ, Childers ME, Keller KL, Ketter TA: **Pilot study of the efficacy of double-blind, placebo-controlled one-week olanzapine stabilization therapy in heterogeneous symptomatic bipolar disorder patients.** *J Psychiatr Res* 2012, **46**(7):920-926.
241. Sukasem C, Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Chamnanphon M, Chamkrachchangpada B, Sinrachatanant A, Limsila P: **Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders.** *Journal of clinical psychopharmacology* 2016, **36**(2):141-146.
242. Sunovion Pharmaceuticals Canada Inc: **Latuda (lurasidone HCl).** In: *CA Product Monograph.* Mississauga, Ontario; 2016.
243. Suppes T, Vieta E, Gustafsson U, Ekholm B: **Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials.** *Depression and anxiety* 2013, **30**(11):1089-1098.
244. Suppes T, Silva R, Cucchiari J, Mao Y, Targum S, Streicher C, Pikalov A, Loebel A: **Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study.** *The American journal of psychiatry* 2016, **173**(4):400-407.
245. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ *et al*: **Pharmacogenetics: from bench to byte--an update of guidelines.** *Clinical pharmacology and therapeutics* 2011, **89**(5):662-673.

246. Szegedi A, Zhao J, van Willigenburg A, Nations KR, Mackle M, Panagides J: **Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials.** *BMC psychiatry* 2011, **11**:101.
247. Szegedi A, Calabrese JR, Stet L, Mackle M, Zhao J, Panagides J: **Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.** *Journal of clinical psychopharmacology* 2012, **32**(1):46-55.
248. Takahashi R, Sakuma A, Itoh K, Itoh H, Kurihara M: **Comparison of efficacy of lithium carbonate and chlorpromazine in mania. Report of collaborative study group on treatment of mania in Japan.** *Archives of general psychiatry* 1975, **32**(10):1310-1318.
249. Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W: **Relationship between the HLA-B\*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis.** *JAMA Dermatology* 2013, **149**(9):1025-1032.
250. Tarr GP, Glue P, Herbison P: **Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania.** *Journal of affective disorders* 2011, **134**(1-3):14-19.
251. Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Chen P, Lin SY, Chen WH, Konyoung P, Khunarkornsiri U, Auvichayapat N, Pavakul K *et al*: **Association between HLA-B\*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population.** *Epilepsia* 2010, **51**(5):926-930.
252. Teva Canada Limited: **Haloperidol.** In: *CA Product Monograph.* Toronto, ON; 2016.
253. Teva Pharmaceuticals USA Inc: **Epitol (carbamazepine).** In: *US Product Monograph.* North Wales, PA; 2015.
254. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R: **Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.** *Journal of clinical psychopharmacology* 2008, **28**(1):13-20.
255. Then SM, Rani ZZ, Raymond AA, Ratnaningrum S, Jamal R: **Frequency of the HLA-B\*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients.** *Asian Pacific journal of allergy and immunology* 2011, **29**(3):290-293.
256. Thomas P, Srivastava V, Singh A, Mathur P, Nimgaonkar VL, Lerer B, Thelma BK, Deshpande SN: **Correlates of response to Olanzapine in a North Indian Schizophrenia sample.** *Psychiatry research* 2008, **161**(3):275-283.
257. Thomas P, Vieta E: **Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial.** *Neuropsychiatric Disease and Treatment* 2008, **4**(3):675-686.
258. Toffol E, Hatonen T, Tanskanen A, Lonnqvist J, Wahlbeck K, Joffe G, Tiihonen J, Haukka J, Partonen T: **Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: A nationwide registry-based prospective cohort study.** *Journal of affective disorders* 2015, **183**:159-165.
259. Toh DS, Tan LL, Aw DC, Pang SM, Lim SH, Thirumoorthy T, Lee HY, Tay YK, Tan SK, Vasudevan A *et al*: **Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study.** *The pharmacogenomics journal* 2014, **14**(4):316-321.

260. Tohen M, Chengappa KN, Suppes T, Zarate CA, Jr., Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC *et al*: **Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.** *Archives of general psychiatry* 2002, **59**(1):62-69.
261. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW *et al*: **Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.** *Archives of general psychiatry* 2003, **60**(11):1079-1088.
262. Tohen M, Bowden CL, Smulevich AB, Bergstrom R, Quinlan T, Osuntokun O, Wang WV, Oliff HS, Martenyi F, Kryzhanovskaya LA *et al*: **Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes.** *The British journal of psychiatry : the journal of mental science* 2008, **192**(2):135-143.
263. Tohen M, McDonnell DP, Case M, Kanba S, Ha K, Fang YR, Katagiri H, Gomez JC: **Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.** *The British journal of psychiatry : the journal of mental science* 2012, **201**(5):376-382.
264. Tondo L, Hennen J, Baldessarini RJ: **Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis.** *Acta psychiatrica Scandinavica* 2001, **104**(3):163-172.
265. Tonzzi TR, Braunstein GD, Kammesheidt A, Curran C, Golshan S, Kelsoe J: **Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study.** *Pharmacogenomics* 2018, **19**(15):1169-1179.
266. Validus Pharmaceuticals LLC: **Equetro (carbamazepine).** In: *US Product Monograph.* Parsippany, NJ; 2016.
267. Vanwong N, Ngamsamut N, Medhasi S, Puangpetch A, Chamnanphon M, Tan-Kam T, Hongkaew Y, Limsila P, Sukasem C: **Impact of CYP2D6 polymorphism on steady-state plasma levels of risperidone and 9-Hydroxyrisperidone in Thai children and adolescents with autism spectrum disorder.** *Journal of child and adolescent psychopharmacology* 2017, **27**(2):185-191.
268. Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD, National Kidney Foundation Kidney Disease Outcomes Quality Initiative: **Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician.** *The American journal of medicine* 2016, **129**(2):153-162 e157.
269. Vasudev A, Macritchie K, Watson S, Geddes JR, Young AH: **Oxcarbazepine in the maintenance treatment of bipolar disorder.** *The Cochrane database of systematic reviews* 2008(1):CD005171.
270. Vasudev A, Macritchie K, Rao SN, Geddes J, Young AH: **Tiagabine in the maintenance treatment of bipolar disorder.** *The Cochrane database of systematic reviews* 2011(12):CD005173.
271. Vieta E, Locklear J, Gunther O, Ekman M, Miltenburger C, Chatterton ML, Astrom M, Paulsson B: **Treatment options for bipolar depression: a systematic review of randomized, controlled trials.** *Journal of clinical psychopharmacology* 2010, **30**(5):579-590.
272. Vieta E, Nuamah IF, Lim P, Yuen EC, Palumbo JM, Hough DW, Berwaerts J: **A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder.** *Bipolar disorders* 2010, **12**(3):230-243.

273. Vieta E, Gunther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML, Astrom M, Paulsson B: **Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials.** *The international journal of neuropsychopharmacology* 2011, **14**(8):1029-1049.
274. Vieta E, Langosch JM, Figueira ML, Souery D, Blasco-Colmenares E, Medina E, Moreno-Manzanaro M, Gonzalez MA, Bellivier F: **Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd).** *The international journal of neuropsychopharmacology* 2013, **16**(8):1719-1732.
275. Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ: **Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance.** *The American journal of psychiatry* 2000, **157**(2):179-184.
276. Wang L, Yu L, Zhang AP, Fang C, Du J, Gu NF, Qin SY, Feng GY, Li XW, Xing QH *et al*: **Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.** *Journal of psychopharmacology (Oxford, England)* 2007, **21**(8):837-842.
277. Wang Q, Zhou JQ, Zhou LM, Chen ZY, Fang ZY, Chen SD, Yang LB, Cai XD, Dai QL, Hong H *et al*: **Association between HLA-B\*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland.** *Seizure* 2011, **20**(6):446-448.
278. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B: **Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder.** *The Journal of clinical psychiatry* 2011, **72**(11):1452-1464.
279. Wu XT, Hu FY, An DM, Yan B, Jiang X, Kwan P, Stefan H, Zhou D: **Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B\*1502 allele among patients in central China.** *Epilepsy & behavior : E&B* 2010, **19**(3):405-408.
280. Xing Q, Qian X, Li H, Wong S, Wu S, Feng G, Duan S, Xu M, Gao R, Qin W *et al*: **The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients.** *The international journal of neuropsychopharmacology* 2007, **10**(5):631-637.
281. Yasui-Furukori N, Kondo T, Suzuki A, Mihara K, Tokinaga N, Inoue Y, Otani K, Kaneko S: **Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol.** *Schizophrenia research* 2001, **52**(1):139-142.
282. Yasui-Furukori N, Tsuchimine S, Saito M, Nakagami T, Sato Y, Kaneko S: **Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients.** *Progress in neuro-psychopharmacology & biological psychiatry* 2007, **31**(6):1230-1234.
283. Yasui-Furukori N, Saito M, Tsuchimine S, Nakagami T, Sato Y, Sugawara N, Kaneko S: **Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.** *Progress in neuro-psychopharmacology & biological psychiatry* 2008, **32**(6):1491-1495.
284. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A: **Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial.** *The British journal of psychiatry : the journal of mental science* 2003, **182**:141-147.

285. Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, Sharma V, Silverstone P, Alda M, Baruch P *et al*: **Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.** *Bipolar disorders* 2005, **7 Suppl 3**:5-69.
286. Yatham LN: **A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder.** *Journal of affective disorders* 2011, **128 Suppl 1**:S21-28.
287. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, Macqueen G, McIntyre RS, Sharma V *et al*: **Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.** *Bipolar disorders* 2013, **15(1)**:1-44.
288. Yatham LN, Beaulieu S, Schaffer A, Kauer-Sant'Anna M, Kapczinski F, Lafer B, Sharma V, Parikh SV, Daigneault A, Qian H *et al*: **Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial.** *Molecular psychiatry* 2016, **21(8)**:1050-1056.
289. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S *et al*: **Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.** *Bipolar disorders* 2018, **20(2)**:97-170.
290. Yildiz A, Vieta E, Leucht S, Baldessarini RJ: **Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials.** *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2011, **36(2)**:375-389.
291. Yildiz A, Nikodem M, Vieta E, Correll CU, Baldessarini RJ: **A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania.** *Psychological medicine* 2015, **45(2)**:299-317.
292. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M: **A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).** *The Journal of clinical psychiatry* 2010, **71(2)**:150-162.
293. Zai CC, De Luca V, Hwang RW, Voineskos A, Muller DJ, Remington G, Kennedy JL: **Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients.** *Molecular psychiatry* 2007, **12(9)**:794-795.
294. Zhang JP, Lencz T, Malhotra AK: **D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.** *The American journal of psychiatry* 2010, **167(7)**:763-772.
295. Zhang Y, Wang J, Zhao LM, Peng W, Shen GQ, Xue L, Zheng XX, He XJ, Gong CY, Miao LY: **Strong association between HLA-B\*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients.** *European journal of clinical pharmacology* 2011, **67(9)**:885-887.
296. Zhang Y, Yang H, Yang S, Liang W, Dai P, Wang C, Zhang Y: **Antidepressants for bipolar disorder: A meta-analysis of randomized, double-blind, controlled trials.** *Neural regeneration research* 2013, **8(31)**:2962-2974.



297. Zhang JP, Lencz T, Zhang RX, Nitta M, Maayan L, John M, Robinson DG, Fleischhacker WW, Kahn RS, Ophoff RA *et al*: **Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis.** *Schizophrenia bulletin* 2016, **42**(6):1418-1437.
298. Zou YF, Wang F, Feng XL, Li WF, Tao JH, Pan FM, Huang F, Su H: **Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders.** *Neuroscience letters* 2010, **484**(1):56-61.